Rigel Pharmaceuticals (RIGL)

$18.93 +0.28 (1.50%)
Market Cap 338.32M
Revenue (ttm) 179.28M
Net Income (ttm) 17.49M
EPS (ttm) N/A
PE Ratio 9.01
Forward PE 8.28
Profit Margin 9.76%
Debt to Equity Ratio 2.42
Volume 97,400
Avg Vol 208,730
Day's Range N/A - N/A
Shares Out 17.87M
Stochastic %K 48%
Beta 1.26
Analysts Sell
Price Target $33.74

Company Profile

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a suscept...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 624 1100
Fax: 650 624 1101
Address:
611 Gateway Boulevard, Suite 900, South San Francisco, United States
MaxKlim
MaxKlim Jul. 3 at 8:49 PM
$RIGL https://clinicaltrials.gov/study/NCT07048964
0 · Reply
Massimo21
Massimo21 Jul. 3 at 2:23 PM
$RIGL From the recent paper entitled Functional cure with single agent olutasidenib in relapsed IDH1/NPM1 co-mutated AML. "Here we report the first patient in the world to receive olutasidenib, for relapsed NPM1 and IDH1 co-mutated AML, who remains in continuous CR for over 7 years on olutasidenib monotherapy."
2 · Reply
elitechrisvp
elitechrisvp Jul. 3 at 12:05 PM
$XBI wait until quantum computing and AI show up in the share price!! 😁 $IBRX $CELU $RIGL
0 · Reply
MaxKlim
MaxKlim Jul. 3 at 12:30 AM
$RIGL https://pubmed.ncbi.nlm.nih.gov/40594997/
0 · Reply
MaxKlim
MaxKlim Jul. 3 at 12:29 AM
$RIGL https://pubmed.ncbi.nlm.nih.gov/40596072/
0 · Reply
MaxKlim
MaxKlim Jul. 2 at 9:55 PM
$RIGL https://pubmed.ncbi.nlm.nih.gov/40599544/
0 · Reply
DailyRips
DailyRips Jul. 2 at 5:54 PM
$RIGL volume is picking the last few days and today ... There's interest in RIGL. Excited to see where it takes us. Bought more shares today and now sitting 2.4k shares
0 · Reply
Gabriel1234
Gabriel1234 Jul. 2 at 4:59 PM
$RIGL Christopher18# as sales increase so does the share
0 · Reply
christopher18
christopher18 Jul. 2 at 3:09 PM
$RIGL What will make this go up and stick instead of us talking about imaginary prices and a bunch of "ifs"!
1 · Reply
Gabriel1234
Gabriel1234 Jul. 2 at 1:47 PM
$RIGL The South Korea launch of TAVALISSE expands its global reach and creates a new royalty revenue stream for Rigel through its licensing deal with Kissei. It also reinforces the drug’s clinical and commercial value. While the immediate financial impact may be modest, it adds to long-term growth.
0 · Reply
Latest News on RIGL
Rigel to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 8:05 AM EDT - 5 weeks ago

Rigel to Present at the Jefferies Global Healthcare Conference

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

May 22, 2025, 5:20 PM EDT - 6 weeks ago

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum

May 7, 2025, 6:16 PM EDT - 2 months ago

Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:13 PM EDT - 2 months ago

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript

Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 4:01 PM EDT - 2 months ago

Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

Apr 29, 2025, 8:05 AM EDT - 2 months ago

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability

Apr 4, 2025, 3:31 PM EDT - 3 months ago

Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Apr 4, 2025, 8:05 AM EDT - 3 months ago

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Mar 27, 2025, 8:05 AM EDT - 3 months ago

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Rigel Appoints Mark W. Frohlich, M.D.

Mar 10, 2025, 8:05 AM EDT - 4 months ago

Rigel Appoints Mark W. Frohlich, M.D.

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 11:29 PM EST - 4 months ago

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 4:01 PM EST - 4 months ago

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Feb 25, 2025, 8:05 AM EST - 4 months ago

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Jan 22, 2025, 8:05 AM EST - 5 months ago

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Rigel Provides Business Update and 2025 Outlook

Jan 13, 2025, 8:05 AM EST - 6 months ago

Rigel Provides Business Update and 2025 Outlook

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Jan 9, 2025, 8:05 AM EST - 6 months ago

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 8:05 AM EST - 6 months ago

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents

Dec 30, 2024, 8:30 AM EST - 6 months ago

Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Dec 9, 2024, 12:02 PM EST - 7 months ago

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Dec 2, 2024, 8:05 AM EST - 7 months ago

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Rigel to Present at the Jefferies London Healthcare Conference

Nov 12, 2024, 8:05 AM EST - 8 months ago

Rigel to Present at the Jefferies London Healthcare Conference

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 10:25 PM EST - 8 months ago

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:01 PM EST - 8 months ago

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Nov 5, 2024, 9:05 AM EST - 8 months ago

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

Oct 31, 2024, 8:05 AM EDT - 8 months ago

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)

Oct 24, 2024, 4:35 PM EDT - 9 months ago

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)

Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®

Oct 16, 2024, 10:00 AM EDT - 9 months ago

Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®

Rigel Pharmaceuticals: Looking For More Growth

Oct 10, 2024, 7:32 AM EDT - 9 months ago

Rigel Pharmaceuticals: Looking For More Growth

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Oct 9, 2024, 8:42 PM EDT - 9 months ago

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Oct 4, 2024, 8:05 AM EDT - 9 months ago

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel to Present at the 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 8:05 AM EDT - 10 months ago

Rigel to Present at the 2024 Cantor Global Healthcare Conference

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

Sep 5, 2024, 7:30 AM EDT - 10 months ago

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan

Sep 3, 2024, 8:00 AM EDT - 10 months ago

Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan

Rigel to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 8:05 AM EDT - 11 months ago

Rigel to Participate in Upcoming September Investor Conferences

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 2:12 PM EDT - 11 months ago

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2024 Earnings Call Transcript

Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 4:01 PM EDT - 11 months ago

Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update

Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update

Jul 30, 2024, 8:05 AM EDT - 1 year ago

Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Jul 24, 2024, 3:06 AM EDT - 1 year ago

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Optime Care Announces Enhanced Partnership with Rigel Pharmaceuticals for GAVRETO® Patients

Jun 27, 2024, 10:00 AM EDT - 1 year ago

Optime Care Announces Enhanced Partnership with Rigel Pharmaceuticals for GAVRETO® Patients

Rigel Announces Reverse Stock Split

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Rigel Announces Reverse Stock Split

Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application

Jun 24, 2024, 4:05 PM EDT - 1 year ago

Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application

Rigel Announces Five Presentations at the EHA2024 Hybrid Congress

Jun 14, 2024, 3:05 AM EDT - 1 year ago

Rigel Announces Five Presentations at the EHA2024 Hybrid Congress

Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting

Jun 3, 2024, 8:13 AM EDT - 1 year ago

Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting

Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

May 23, 2024, 5:00 PM EDT - 1 year ago

Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2024 Earnings Call Transcript

May 7, 2024, 9:46 PM EDT - 1 year ago

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2024 Earnings Call Transcript

Rigel Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 4:01 PM EDT - 1 year ago

Rigel Reports First Quarter 2024 Financial Results and Provides Business Update

Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update

Apr 30, 2024, 8:05 AM EDT - 1 year ago

Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update

Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

Apr 4, 2024, 8:05 AM EDT - 1 year ago

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

Mar 12, 2024, 8:05 AM EDT - 1 year ago

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

MaxKlim
MaxKlim Jul. 3 at 8:49 PM
$RIGL https://clinicaltrials.gov/study/NCT07048964
0 · Reply
Massimo21
Massimo21 Jul. 3 at 2:23 PM
$RIGL From the recent paper entitled Functional cure with single agent olutasidenib in relapsed IDH1/NPM1 co-mutated AML. "Here we report the first patient in the world to receive olutasidenib, for relapsed NPM1 and IDH1 co-mutated AML, who remains in continuous CR for over 7 years on olutasidenib monotherapy."
2 · Reply
elitechrisvp
elitechrisvp Jul. 3 at 12:05 PM
$XBI wait until quantum computing and AI show up in the share price!! 😁 $IBRX $CELU $RIGL
0 · Reply
MaxKlim
MaxKlim Jul. 3 at 12:30 AM
$RIGL https://pubmed.ncbi.nlm.nih.gov/40594997/
0 · Reply
MaxKlim
MaxKlim Jul. 3 at 12:29 AM
$RIGL https://pubmed.ncbi.nlm.nih.gov/40596072/
0 · Reply
MaxKlim
MaxKlim Jul. 2 at 9:55 PM
$RIGL https://pubmed.ncbi.nlm.nih.gov/40599544/
0 · Reply
DailyRips
DailyRips Jul. 2 at 5:54 PM
$RIGL volume is picking the last few days and today ... There's interest in RIGL. Excited to see where it takes us. Bought more shares today and now sitting 2.4k shares
0 · Reply
Gabriel1234
Gabriel1234 Jul. 2 at 4:59 PM
$RIGL Christopher18# as sales increase so does the share
0 · Reply
christopher18
christopher18 Jul. 2 at 3:09 PM
$RIGL What will make this go up and stick instead of us talking about imaginary prices and a bunch of "ifs"!
1 · Reply
Gabriel1234
Gabriel1234 Jul. 2 at 1:47 PM
$RIGL The South Korea launch of TAVALISSE expands its global reach and creates a new royalty revenue stream for Rigel through its licensing deal with Kissei. It also reinforces the drug’s clinical and commercial value. While the immediate financial impact may be modest, it adds to long-term growth.
0 · Reply
MaxKlim
MaxKlim Jul. 2 at 12:04 PM
$RIGL July 1, 2025 Kissei Pharmaceutical Co., Ltd. (Code 4547, Tokyo Stock Exchange Prime Market) New Launch of TAVALISSE® for Chronic Idiopathic Thrombocytopenic Purpura Treatment in South Korea Kissei Pharmaceutical Co., Ltd. (Head Office: Matsumoto, Nagano, Japan; Chairman and CEO: Mutsuo Kanzawa; “Kissei”) announced that its licensing partner, JW Pharmaceutical Corporation (Head Office: The Republic of Korea, CEO: YS Shin; "JWP"), has launched the spleen tyrosine kinase (SYK) inhibitor TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic idiopathic thrombocytopenic purpura (ITP) who have had an insufficient response to a previous treatment in South Korea under the brand name "TAVALISSE" on July 1, 2025. and is indicated TAVALISSE is an oral SYK inhibitor discovered by Rigel Pharmaceuticals, Inc. (Head Office: USA, President and CEO, Raul Rodriguez; "Rigel").
0 · Reply
MaxKlim
MaxKlim Jul. 2 at 11:43 AM
$RIGL https://www.kissei.co.jp/e_contents/news/uploaded/fb4fa538f9da51661eef62cad3b63e28.pdf
0 · Reply
Dohtem
Dohtem Jul. 2 at 4:05 AM
$RIGL realistically, Rigel has to be one of the best stock to short for a day trader. scalp every morning.
1 · Reply
B4I4QQTRU18
B4I4QQTRU18 Jul. 2 at 1:08 AM
$RIGL last year we were buying/adding at 7.80 ish. It’s been a good year. And now with a real PE below 10, I expect next July we will be real happy too.
0 · Reply
Ou8mycookie
Ou8mycookie Jul. 1 at 4:52 PM
$RIGL kymera’s irark 4 protein degrader in phase 2 was dropped for an earlier stage irak4 degrader by Sanofi. Not sure why but I think it’s good news for Rigl as they have not given up on the irak4 inhibition and sets them back years in development which could be potential competition. But it’s hard to block the pathways via protein degradation in vivo as is not as selective( so not as safe) even though in vitro the molecule could work fine. Also indirectly related to ripk1 neuro development by Lilly is Inmunes latest AD results with a sub pop group in their trial showing positive results in patients with neuro inflammation. Their drug xpro inhibits TNF as does ripk1 molecules. It’s estimated that could be a 5 billion TAM. Shows some clinical evidence in the concept and shows the interest that Lilly had in developing a brain penetrate ripk1. I think all of the above is somewhat positive for Rigel and gives us some clues on the efficacy of the target pathways.
0 · Reply
GO_DAWGS
GO_DAWGS Jul. 1 at 4:28 PM
$RIGL hope no one lost their shares!
1 · Reply
MaxKlim
MaxKlim Jul. 1 at 4:15 PM
$RIGL https://pubmed.ncbi.nlm.nih.gov/40586049/
0 · Reply
GO_DAWGS
GO_DAWGS Jul. 1 at 12:34 PM
$RIGL 🤔 Institutional Shares (Long) 15,792,076 - 88.36% (ex 13D/G) - change of 3.60MM shares 29.52% MRQ
1 · Reply
christopher18
christopher18 Jun. 30 at 4:32 PM
$RIGL They said it was the market reaction with the tariffs.... Well, the market is now up to 44k points. What's the logic now?
0 · Reply
Namhguab
Namhguab Jun. 30 at 4:04 PM
$RIGL Raul, just say your plan is to fund a bitcoin treasury strategy lmfao. How stupid is this damn market right now?
1 · Reply
Berakhot
Berakhot Jun. 30 at 3:23 PM
$RIGL error, meant for $MDAI post. oh well, @ 2.44 now.
0 · Reply
Berakhot
Berakhot Jun. 30 at 2:55 PM
$RIGL Analyst Targets/Multiples Forward P/E: ~11.3× EV/Sales: ~1.83 (undervalue) Analyst Targets: ~$36.40 avg, w/highs near $57 Trading ~1.7 price-to-sales ratio. Low for profitable biotech w/3 commercial drugs (TAVALISSE, REZLIDHIA, GAVRETO). Pipeline could add much greater value.
0 · Reply